Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19

• Status: Active, not recruiting
• Trial end date: 2021-09-30
• Target enrollment: 0
• Participant gender: All

Summary

This single-center, open-label, 2 arm parallel-group, randomized, interventional prospective exploratory study in 20 subjects aimed to evaluate safety and explore putative clinical benefits of Silmitasertib 1000 mg BID dose in patients with moderate COVID-19. Two-arm trial comparing the SOC/supportive care alone to the SOC/supportive care with addition of Silmitasertib (allocation ratio 1:1).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chris Recknor, MD

Criteria

Inclusion Criteria:

1. Male or non-pregnant female adult ≥ 18 years of age

2. Diagnosed with COVID-19 by standard RT-PCR assay or equivalent testing

3. Outpatient subjects with moderate illness caused by SARS-CoV-2 infection as defined below,

• Symptoms of moderate systemic illness/infection with COVID-19:

At least two of the key COVID-19-related symptoms with score 2 or higher (0=none, 1=mild, 2=moderate, and 3=severe): cough, sore throat, malaise, headache, muscle pain, fever, neurological symptoms such as brain fog/concentration challenges, gastrointestinal symptoms or shortness of breath with exertion

AND

• Clinical signs indicative of moderate systemic illness/infection with COVID-19 At least 1 of the following: respiratory rate ≥ 20 breaths per minute, heart rate ≥ 90 beats per minute

AND

• No clinical signs indicative of Severe or Critical Illness Severity required hospitalization (see exclusion criterion #1)

4. Patient (or legally authorized representative) provides written informed consent prior to initiation of any study procedures.

5. Adequate hematopoietic capacity, as defined by the following:

1. Hemoglobin ≥ 9.0 g/dL and not transfusion dependent

2. Platelets ≥ 100,000/mm3

3. Absolute neutrophil count ≥ 1500 cells/mm3

6. Adequate hepatic function, as defined by the following:

1. AST and ALT ≤ 2.5 times upper limit of normal (ULN)

2. Total bilirubin ≤ 1.5 x ULN

3. Albumin ≥ 3.0 g/dL

7. Adequate renal function, as defined by the following:

a. Renal: calculated creatinine clearance >45 mL/min for patients with abnormal, increased creatinine levels (Cockcroft-Gault formula).

8. Ability to take oral medication and be willing to adhere to drug administration and premedication requirements (see Section 6.3) throughout study duration.

Exclusion Criteria:

1. Any signs indicative of Severe or Critical Illness Severity required hospitalization as defined below:

• Severe COVID-19: Shortness of breath in rest, or respiratory distress, respiratory rate (RR) >/= 30 per minute, heart rate (HR) >/=125 bpm, SpO2on room air at sea level or PaO2/FiO2<300

• Critical COVID-19: respiratory failure required mechanical ventilation, oxygen delivered by high-flow nasal cannula, ESMO; shock or multi-organ dysfunction/failure

2. Pregnant or nursing women. (NOTE: Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) prior to study entry and for the duration of study participation. Should a man father a child, or a woman become pregnant or suspect she is pregnant while participating in this study, he or she should inform the treating physician immediately.)

3. Active or uncontrolled infections other than COVID-19 or with serious illnesses or medical conditions which would not permit the patient to receive study treatment

4. Chronic diarrhea (excess of 2-3 stools/day above normal frequency)

5. Concomitant treatment with another investigational drug from Day 1 through Day 28.

6. Current use or anticipated need for drugs that are known strong inhibitors or inducers of major CYP enzymes.